ライフサイエンスコーパス: placebo group

1 Baseline variables in the 98 pomegranate juice and 102 placebo group subjects who completed the study did not differ

2 not significantly differ between the hydroxychloroquine and placebo groups (median [IQR] score, 6 [4-7] vs 6 [4-7]; aOR,

3 5.5 to 2.5; P = .47) and between the 10-mg/d vericiguat and placebo groups was -0.5 (95% CI, -4.6 to 3.5; P = .80).

4 ean difference in scores between the 15-mg/d vericiguat and placebo groups was -1.5 (95% CI, -5.5 to 2.5; P = .47) and be

5 n scores in the 15-mg/d vericiguat, 10-mg/d vericiguat, and placebo groups were 295.0 m and 311.8m , 292.1 m and 318.3 m,

6 the APOLLO-patisiran group, 38 (78%) of 49 from the APOLLO-placebo group, and 25 (100%) of 25 from the phase 2 OLE patis

7 acebo group (+5% +/- 12% in FMT group versus -3% +/- 32% in placebo group, mean difference 9%, 95% CI -5% to 28%, p = 0.1

8 dified intention-to-treat population, and 397 (102 [94%] in placebo group, 102 [94%] in 100 mg group, 98 [89%] in 200 mg

9 Of these patients, 434 (106 [98%] in placebo group, 108 [100%] in 100 mg group, 109 [99%] in 200 m

10 We studied 53 newly diagnosed subjects enrolled in placebo groups of TrialNet clinical trials.

11 to the adjuvanted vaccine (n=17), vaccine alone (n=16), or placebo group (n=16).

12 s through day 5) was similar in the LY-CoV555 group and the placebo group (19% and 14%, respectively; odds ratio, 1.56; 9

13 ificant difference between the erythropoietin group and the placebo group in the incidence of death or severe neurodevelo

14 CSF SOD1 concentration between the tofersen groups and the placebo group was 2 percentage points (95% confidence interva

15 d every 8 weeks group (66 [52%] of 127 [43-61]) than in the placebo group (28 [22%] of 126 [15-30]), with percentage diff

16 6.0% of infants in the DHA group vs 10.2% of infants in the placebo group (absolute difference, -3.9% [95% CI, -6.8% to 1

17 -72) in the pertuzumab group and 40.8 months (36-48) in the placebo group (hazard ratio 0.69, 95% CI 0.58-0.82); 8-year l

18 lated to nab-paclitaxel [n=1]) and one (<1%) patient in the placebo group (hepatic failure).

19 ) in the colchicine group and in 264 patients (9.6%) in the placebo group (incidence, 2.5 vs. 3.6 events per 100 person-y

20 d 1.1 (IQR, 0.1-6.6) minutes per hour among patients in the placebo group (P = .29), with an estimated median difference

21 in the ferric carboxymaltose group and 294 occurred in the placebo group (RR 0.74; 95% CI 0.58-0.94, p=0.013).

22 ing among 6 patients [12%]) versus 14 patients (30%) in the placebo group (with 6 infectious serious adverse events devel

23 total of 4002 children underwent randomization (1999 in the placebo group and 2003 in the amoxicillin group).

24 r proportions of patients in each group had AEs (42% in the placebo group and 32% in the nabilone group).

25 baseline to 3 mo) in serum vitamin D3 was -0.1 ng/mL in the placebo group and 6.8 ng/mL in the 2000 IU/d group (absolute

26 pants (37.5%) in the vitamin D3 group and 33 (34.4%) in the placebo group had 1 or more severe exacerbations.

27 s in the tocilizumab group and 21.2% of the patients in the placebo group were still receiving supplemental oxygen.

28 sessed to be better in the melatonin group than that in the placebo group with a mean (SD) of 69.7 (21.2) and 60.7 (26.3)

29 60 (57%) of 104 patients in the placebo group, 63 (66%) of 96 in the ixekizumab Q4W group, an

30 group and an increase of 8.2% (95% CI, 4.3 to 12.2) in the placebo group, for a between-group difference of -47.9 percen

31 12% in the placebo group, p&0.05).

32 51.0% of the patients in the 300 IR group and 14.9% in the placebo group.

33 (SD 10.6) in the azithromycin group and 90.4% (10.1) in the placebo group.

34 3.3) in the nivolumab group and 6.4 months (3.3-9.6) in the placebo group.

35 5% CI 31-42) in the pertuzumab group and 23% (19-28) in the placebo group.

36 20 patients in the ticagrelor group and 223 patients in the placebo group.

37 42) of participants in the active and 51.7% (76/147) in the placebo group.

38 brocitinib 200 mg group, and 44 (57%) of 77 patients in the placebo group.

39 he IVIG group were responders, compared to zero of 6 in the placebo group.

40 One patient died by sudden death in the placebo group.

41 g scale (-11.5 in the zoledronic acid group vs -16.8 in the placebo group; between-group difference, 5.2 [95% CI, -2.3 to

42 nts in insulin sensitivity in the FMT group compared to the placebo group (+5% +/- 12% in FMT group versus -3% +/- 32% in

43 andomization (608 to the sotagliflozin group and 614 to the placebo group) and were followed for a median of 9.0 months;

44 ned to the rivaroxaban group, and 3278 were assigned to the placebo group.

45 ients were assigned to the intervention group and 52 to the placebo group.

46 tients were assigned to the SEP-363856 group and 125 to the placebo group.

47 ignificantly shorter in the steroid group compared with the placebo group even though both groups included patients who w

48 ficantly improved in the pertuzumab group compared with the placebo group.

49 among participants receiving canakinumab compared with the placebo group.

50 -related complications in the pimodivir group (7.9%) versus placebo group (15.6%).